Aclarion, Inc. ACON
We take great care to ensure that the data presented and summarized in this overview for Aclarion, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ACON
Top Purchases
Top Sells
About ACON
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Insider Transactions at ACON
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2023
|
Jeffrey John Thramann Executive Chairman |
SELL
Other acquisition or disposition
|
Direct |
1
-100.0%
|
$1,000
$1000.0 P/Share
|
|
Feb 16
2023
|
Jeffrey John Thramann Executive Chairman |
BUY
Open market or private purchase
|
Direct |
1
+50.0%
|
$1,000
$1000.0 P/Share
|
|
Dec 29
2022
|
Brent Ness Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
16,211
+35.12%
|
$0
$0.55 P/Share
|
|
Dec 29
2022
|
John Paul Lorbiecki Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
22,404
+47.48%
|
$0
$0.44 P/Share
|
|
Dec 28
2022
|
Brent Ness Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,289
+41.04%
|
$0
$0.42 P/Share
|
|
Dec 02
2022
|
David K Neal Director |
SELL
Other acquisition or disposition
|
Direct |
152,128
-44.92%
|
-
|
|
Dec 02
2022
|
Sc Capital 1 LLC |
SELL
Other acquisition or disposition
|
Direct |
1,091,894
-100.0%
|
-
|
|
Apr 22
2022
|
Ryan Bond Chief Strategy Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$40,000
$2.8 P/Share
|
|
Apr 21
2022
|
David K Neal Director |
BUY
Open market or private purchase
|
Direct |
34,400
+50.0%
|
$137,600
$4.35 P/Share
|
|
Apr 21
2022
|
Brent Ness Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$4,000
$4.35 P/Share
|
|
Apr 21
2022
|
William Wesemann Director |
BUY
Open market or private purchase
|
Direct |
11,000
+17.26%
|
$44,000
$4.35 P/Share
|